Royal Bank of Canada’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $127K | Sell |
2,100
-23,300
| -92% | -$1.36M | ﹤0.01% | 4990 |
|
|
2025
Q4 | $1.37M | Buy |
25,400
+15,400
| +154% | +$741K | ﹤0.01% | 3420 |
|
|
2025
Q3 | $451K | Buy |
+10,000
| New | +$467K | ﹤0.01% | 4567 |
|
|
2023
Q4 | – | Sell |
-90,000
| Closed | -$5.22M | – | 7125 |
|
|
2023
Q3 | $5.22M | Buy |
+90,000
| New | +$5.51M | ﹤0.01% | 2054 |
|
|
2021
Q1 | – | Sell |
-375,000
| Closed | -$23.3M | – | 7426 |
|
|
2020
Q4 | $23.3M | Hold |
375,000
| – | – | 0.01% | 1147 |
|
|
2020
Q3 | $22.6M | Hold |
375,000
| – | – | 0.01% | 1011 |
|
|
2020
Q2 | $22.1M | Sell |
375,000
-157,500
| -30% | -$9.42M | 0.01% | 981 |
|
|
2020
Q1 | $29.7M | Sell |
532,500
-502,800
| -49% | -$30.7M | 0.01% | 704 |
|
|
2019
Q4 | $66.5M | Buy |
1,035,300
+2,800
| +0.3% | +$160K | 0.02% | 520 |
|
|
2019
Q3 | $52.4M | Sell |
1,032,500
-106,600
| -9% | -$5.01M | 0.02% | 572 |
|
|
2019
Q2 | $51.7M | Sell |
1,139,100
-2,580,200
| -69% | -$120M | 0.02% | 577 |
|
|
2019
Q1 | $177M | Buy |
3,719,300
+2,655,100
| +249% | +$132M | 0.08% | 233 |
|
|
2018
Q4 | $55.3M | Buy |
1,064,200
+354,200
| +50% | +$19M | 0.03% | 489 |
|
|
2018
Q3 | $44.1M | Sell |
710,000
-970,300
| -58% | -$57.6M | 0.02% | 643 |
|
|
2018
Q2 | $93M | Buy |
1,680,300
+1,301,300
| +343% | +$70.3M | 0.04% | 344 |
|
|
2018
Q1 | $24M | Sell |
379,000
-287,400
| -43% | -$18.5M | 0.01% | 970 |
|
|
2017
Q4 | $40.8M | Hold |
666,400
| – | – | 0.02% | 712 |
|
|
2017
Q3 | $42.5M | Sell |
666,400
-223,300
| -25% | -$13M | 0.02% | 647 |
|
|
2017
Q2 | $49.6M | Buy |
889,700
+186,700
| +27% | +$10.2M | 0.03% | 541 |
|
|
2017
Q1 | $38.2M | Buy |
703,000
+536,300
| +322% | +$29.4M | 0.02% | 647 |
|
|
2016
Q4 | $9.74M | Buy |
166,700
+51,700
| +45% | +$2.83M | 0.01% | 1530 |
|
|
2016
Q3 | $6.2M | Sell |
115,000
-13,900
| -11% | -$893K | ﹤0.01% | 1766 |
|
|
2016
Q2 | $9.48M | Buy |
128,900
+28,600
| +29% | +$2.02M | 0.01% | 1492 |
|
|
2016
Q1 | $6.41M | Sell |
100,300
-166,300
| -62% | -$10.5M | ﹤0.01% | 1662 |
|
|
2015
Q4 | $18.3M | Buy |
266,600
+8,500
| +3% | +$562K | 0.01% | 1025 |
|
|
2015
Q3 | $15.3M | Buy |
258,100
+82,200
| +47% | +$5.21M | 0.01% | 915 |
|
|
2015
Q2 | $11.7M | Sell |
175,900
-274,100
| -61% | -$18.1M | 0.01% | 1138 |
|
|
2015
Q1 | $29M | Buy |
450,000
+293,000
| +187% | +$18.3M | 0.02% | 618 |
|
|
2014
Q4 | $9.27M | Buy |
157,000
+127,000
| +423% | +$7.16M | 0.01% | 1256 |
|
|
2014
Q3 | $1.53M | Hold |
30,000
| – | – | ﹤0.01% | 2520 |
|
|
2014
Q2 | $1.46M | Buy |
+30,000
| New | +$1.48M | ﹤0.01% | 2526 |
|
Other funds holding BMY
VCM
VPM
Royal Bank of Canada's BMY Position: Q1 2026 in Review
Royal Bank of Canada reduced its Bristol-Myers Squibb (BMY) stake by 13% in Q1 2026, selling an estimated $98.2M and leaving 10,958,702 shares worth $665M. The position accounts for 0.12% of the portfolio, ranked #167.
Royal Bank of Canada first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $816M in Q1 2025. 2,527 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Royal Bank of Canada held 10,958,702 shares of Bristol-Myers Squibb worth $665M as of Q1 2026.
- Royal Bank of Canada sold 1,684,783 Bristol-Myers Squibb shares in Q1 2026, an estimated $98.2M.
- Bristol-Myers Squibb made up 0.12% of Royal Bank of Canada's portfolio in Q1 2026, its #167 holding.
- Royal Bank of Canada first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Bristol-Myers Squibb position peaked at $816M in Q1 2025.
- 2,527 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.